VAXum, LLC
5Patents
5Active
5Granted
41Portfolio score
Filing activity: Nov 12, 2003 → Sep 13, 2016 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8119117B2 | Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunity | Chemistry; Metallurgy | 23 | Active |
| US8236295B1 | Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responses | Chemistry; Metallurgy | 5 | Active |
| US8540979B2 | Methods of generating immune responses with compositions comprising an adenoviral expression vector comprising a CD40L fusion protein | Chemistry; Metallurgy | 2 | Active |
| US9458221B2 | Adenoviral expression vector encoding a CD40L fusion protein | Chemistry; Metallurgy | 1 | Active |
| US11027006B2 | Adenoviral vector vaccine | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.